advertisement
Wang SY 5
Showing records 1 to 5 |
Display all abstracts from Wang SY96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesBeykin G
American Journal of Ophthalmology 2021; 234: 223-234
96169 The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records DatabaseLee EB; Hu W
Ophthalmology 2022; 129: 276-284
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesStell L; Halim MS
American Journal of Ophthalmology 2021; 234: 223-234
96169 The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records DatabaseSingh K; Wang SY
Ophthalmology 2022; 129: 276-284
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesNuñez M; Popova L; Nguyen BT; Groth SL; Dennis A; Li Z; Atkins M; Khavari T; Wang SY; Chang R; Fisher AC; Sepah YJ; Goldberg JL
American Journal of Ophthalmology 2021; 234: 223-234
Issue 22-3
Change Issue
advertisement